Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2B | P29275 | 9/20 | 0.56 |
| ▸ | ADORA2A | P29274 | 9/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | PDE4A | P27815 | 1/20 | 0.41 |
| ▸ | BLM | P54132 | 1/20 | 0.41 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.41 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.41 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1497286 | 0.90 | ADORA2B (0.57) | ADORA2BADORA2ACYP1A2CYP3A4PDE4A | |
| SCHEMBL1497229 | 0.86 | ADORA2B (0.67) | ADORA2BADORA2ACYP1A2CYP3A4PDE4A | |
| SCHEMBL7031251 | 0.80 | ADORA2B (0.71) | ADORA2BADORA2ACYP1A2CYP3A4PDE4A | |
| SCHEMBL7037369 | 0.75 | ADORA2B (0.88) | ADORA2BADORA2ACYP1A2CYP3A4HSD17B10 | |
| SCHEMBL4467031 | 0.73 | ADORA2B (0.67) | ADORA2BADORA2ACYP1A2CYP3A4PDE4A | |
| SCHEMBL1001096 | 0.72 | ADORA2B (0.67) | ADORA2BADORA2ACYP1A2CYP3A4HSD17B10 | |
| SCHEMBL14344322 | 0.71 | ADORA2B (0.68) | ADORA2BADORA2AADORA3 | |
| SCHEMBL3632524 | 0.70 | GRM5 (0.59) | — | |
| SCHEMBL7034258 | 0.69 | ADORA2B (0.56) | ADORA2BADORA2ACYP1A2CYP3A4PDE4A | |
| SCHEMBL3633794 | 0.68 | MEN1 (0.50) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1894250-B | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS LLC | 2010-06-09 | — | — | CN | claimed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | claimed |
| CN-1894250-A | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS LLC (US) | 2007-01-10 | — | — | CN | claimed |
| EP-1658291-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | Adenosine Therapeutics, LLC (US) | 2006-05-24 | — | — | EP | claimed |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ALLERGAN SALES, LLC | 2005-03-24 | — | — | US | claimed |
| WO-2005021548-A2 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADENOSINE THERAPEUTICS, LLC (US) | 2005-03-10 | — | — | WO | claimed |
| EP-2295434-B1 | Substituted 8-heteroaryl xanthines | DOGWOOD PHARMACEUTICALS INC (US) | 2015-09-30 | — | — | EP | disclosed |
| EP-1658291-B1 | SUBSTITUTED 8-HETEROARYL XANTHINES | DOGWOOD PHARMACEUTICALS INC (US) | 2013-10-02 | — | — | EP | disclosed |
| CN-101851238-B | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS LLC | 2012-07-18 | — | — | CN | disclosed |
| EP-2295434-A2 | Substituted 8-heteroaryl xanthines | Adenosine Therapeutics, LLC (US) | 2011-03-16 | — | — | EP | disclosed |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | PGXHEALTH, LLC (US) | 2010-10-28 | — | — | US | disclosed |
| CN-101851238-A | The 8-heteroaryl xanthine that replaces | ADENOTHERAPEUTICS LLC | 2010-10-06 | — | — | CN | disclosed |
| CN-1894250-B | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS LLC | 2010-06-09 | — | — | CN | disclosed |
| US-7732455-B2 | Substituted 8-heteroaryl xanthines | PGX HEALTH, LLC (US) | 2010-06-08 | — | — | US | disclosed |
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ALLERGAN SALES, LLC | 2008-08-21 | — | — | US | disclosed |
| US-7342006-B2 | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-11 | — | — | US | disclosed |
| CN-1894250-A | Substituted 8-heteroaryl xanthines | ADENOSINE THERAPEUTICS LLC (US) | 2007-01-10 | — | — | CN | disclosed |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ALLERGAN SALES, LLC | 2005-03-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200456-A1 | Substituted 8-Heteroaryl Xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885CYP1A2 203/4885 |
| US-20050065341-A1 | Substituted 8-heteroaryl xanthines | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885CYP1A2 203/4885 |
| US-20100273780-A1 | SUBSTITUTED 8-HETEROARYL XANTHINES | ADORA2B, ADORA2A, ADORA3 | ADORA2B 1/4885ADORA2A 2/4885CYP1A2 203/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.